Vaxil Bio Ltd. (TSXV: VXL)
Health Care · Biotechnology · CA
CA$0.15
-3.33% today · -21.6% 1Y
Vaxil Bio Ltd. (TSXV: VXL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $405.24K and employs 3 people.
Over the last twelve months the share price has lost 21.6%, trading between 0.13 and 0.29.
Tweenvest scores Vaxil Bio Ltd. across four factors: quality 43/100, value 22/100. Its strongest factor is quality.
VXL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $405.24K
- Revenue (TTM)
- —
- P/E
- 1.33
- EPS
- 0.11
- Dividend yield
- —
- Beta (5Y)
- -0.33
- 52-week high
- CA$0.29
- 52-week low
- CA$0.13
- Avg volume (3M)
- —
- Shares outstanding
- 3.98M
- Employees
- 3
- Next earnings
- —
About Vaxil Bio Ltd.
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
- ISIN
- CA92243L2066
- Listed since
- Mar 30, 2010
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ludwig Enterprises, Inc.OTCPK: LUDG | $585.08K | $0.00 | -65.00% |
| IntegraGen SAENXTPA: ALINT | $519.56K | €0.04 | -40.86% |
| NovelStem International Corp.OTCPK: NSTM | $468.66K | $0.01 | -7.41% |
| Sorrento Therapeutics, Inc.OTCPK: SRNE | $434.97K | $0.00 | +166.67% |
| Asia Green Biotechnology Corp.CNSX: ASIA | $400.48K | CA$— | — |
| Actavia Life Sciences, Inc.OTCPK: RASP | $385.91K | $— | — |
| Waverley Pharma Inc.TSXV: WAVE | $385.12K | CA$0.01 | -33.33% |
| Paion AGDB: PA8K | $369.33K | €0.05 | -9.80% |
Figures last refreshed Oct 4, 2026.